Sophiris Bio Inc SPHS

Healthcare Biotechnology

Sophiris Bio Inc is a clinical-stage biopharmaceutical company. It focuses on the development of products for the treatment of urological diseases. The company's product portfolio includes topsalysin (PRX302), for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. Topsalysin is a genetically modified recombinant protein which is selectively activated by enzymatically active prostate-specific antigen (PSA), which is only present in the prostate, leading to localized cell death and tissue disruption without damage to neighboring tissue and nerves. Geographically all the operations of the company are functioned in the United States.

EXPM:SPHS - Post by User

Sophiris Bio Inc

Bullboard Posts

Post by rythmanon Jun 06, 2014 3:56pm

121 Views

Post# 22638698

Can't feel bad buying here..

Aspire paid $3.31 per share for 604,000 shares. How do you thinnk they feel losing roughly 33% of thier investment.
Nice to see someone else on this board.
cheers rythman

Bullboard Posts

BMO evolves InvestorLine with enhanced tools for options trading